Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of BMF-219 monotherapy in relapsed or refractory hematologic malignancies
NL-OMON55976Phase 1Recruiting
- Sponsor
- Biomea Fusion
- Start
- Jun 2023
- Modality
- Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of icovamenib in Acute Leukaemia, diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and 1 more (5 cohorts), sponsored by Biomea Fusion. Primary endpoint: Optimal biologic dose and recommended phase 2 dose. Started Jun 2023; status: recruiting.
02
Drugs
icovamenib
03
Conditions
Acute Leukaemiadiffuse large B-cell lymphoma (DLBCL)multiple myeloma (MM)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON55976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55976.